文献速递类风湿关节炎

SIK抑制剂HG-9-91-01抑制类风湿关节炎成纤维样滑膜细胞的致病活性

SIK inhibitor HG-9-91-01 suppresses the pathogenic activity of fibroblast-like synoviocytes in rheumatoid arthritis.
PubMed 文献 · RMD Open · 2026-08-20

本研究探讨SIK抑制剂HG-9-91-01对类风湿关节炎(RA)成纤维样滑膜细胞(FLS)致病性的影响及机制。体外实验显示HG-9-91-01抑制MH7A细胞增殖、迁移和侵袭并促进凋亡,机制涉及同时抑制PI3K-Akt和NF-κB通路;在胶原诱导性关节炎(CIA)小鼠中,HG-9-91-01减轻关节炎严重程度、滑膜炎、软骨降解和骨侵蚀。

要点

  • SIK3在RA滑膜组织中显著上调并与疾病活动度相关。
  • HG-9-91-01通过双重抑制PI3K-Akt和NF-κB通路降低FLS致病性。
  • HG-9-91-01在CIA小鼠中减轻关节炎严重程度和骨侵蚀。

核心结论

  • HG-9-91-01通过双重抑制PI3K-Akt和NF-κB信号通路直接靶向FLS致病性,从而减缓RA进展,提示抑制SIK家族在RA中具有治疗潜力。

研究设计与样本

  • 体外研究使用人MH7A细胞,采用CCK-8、EdU、流式细胞术、划痕愈合和Transwell实验评估HG-9-91-01的影响,并通过RNA测序、生物信息学分析和western blot探索机制。
  • 体内研究在鼠胶原诱导性关节炎(CIA)模型中通过临床评分、组织病理学和micro-CT成像评估HG-9-91-01的治疗效果。

主要发现

  • SIK3在RA滑膜组织中显著上调并与疾病活动度相关。
  • HG-9-91-01强效抑制MH7A细胞增殖、迁移和侵袭,同时促进凋亡。
  • 转录组和分子分析显示上述效应通过同时抑制PI3K-Akt和NF-κB信号通路介导,下游调节Bax、Bcl-2、iNOS、TNF-α和MMP-9。
  • 在CIA小鼠中,给予HG-9-91-01显著减轻关节炎严重程度、滑膜炎、软骨降解和骨侵蚀。

临床怎么用

  • HG-9-91-01作为SIK抑制剂在临床前研究中显示通过靶向FLS致病性减缓RA进展,提示SIK家族抑制可能成为RA治疗策略,但尚未进入临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterised by synovial inflammation and joint destruction, in which fibroblast-like synoviocytes (FLS) play a pivotal role through their hyperproliferative, invasive and inflammatory properties. The salt-inducible kinase (SIK) family regulates inflammatory responses, yet the role of its isoform SIK3 in RA and the therapeutic potential of its inhibition remain unclear. This study investigates the effects of HG-9-91-01, a potent SIK inhibitor, on RA-FLS pathogenicity and disease progression. METHODS: The impact of HG-9-91-01 on human MH7A cells was assessed using cell counting kit-8, 5-ethynyl-2'-deoxyuridine, flow cytometry, wound healing and Transwell assays. RNA sequencing, bioinformatics analyses and western blot analysis were employed to explore the underlying mechanisms. The therapeutic efficacy of HG-9-91-01 was evaluated in a murine collagen-induced arthritis (CIA) model through clinical scoring, histopathology and micro-CT imaging. RESULTS: SIK3 was significantly upregulated in RA synovial tissues and correlated with disease activity. HG-9-91-01 potently inhibited MH7A cell proliferation, migration and invasion while promoting apoptosis. Transcriptomic and molecular analyses revealed that these effects were mediated through the concurrent suppression of the phosphoinositide 3-kinase-protein kinase B (PI3K-Akt) and nuclear factor kappa B (NF-κB) signalling pathways, leading to downstream modulation of Bcl-2-associated X protein, B-cell lymphoma 2, inducible nitric oxide synthase, tumour necrosis factor-α and matrix metalloproteinase-9. In CIA mice, HG-9-91-01 administration markedly alleviated arthritis severity, synovitis, cartilage degradation and bone erosion. CONCLUSIONS: Our findings demonstrate that HG-9-91-01 attenuates RA progression by directly targeting FLS pathogenicity via dual inhibition of PI3K-Akt and NF-κB signalling, highlighting the therapeutic potential of SIK family inhibition in RA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Wang X, Li Y, Li H, et al. SIK inhibitor HG-9-91-01 suppresses the pathogenic activity of fibroblast-like synoviocytes in rheumatoid arthritis. RMD Open. 2026. PMID: 42624615. doi:10.1136/rmdopen-2026-007000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。